SOURCE: Equity Markets, Inc.

June 17, 2011 09:00 ET

Research Report on Allos Therapeutics, Inc. and Spectrum Pharmaceuticals, Inc. -- BioPharm Looks Forward for Growth

MACAU--(Marketwire - Jun 17, 2011) - Today, announced its research report highlighting Allos Therapeutics, Inc. (NASDAQ: ALTH) and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). Full content and research is available at

While it is thought that the recent health care reform legislation will negatively affect industry profitability over the next few years, new innovations within the healthcare field have maintained an influx of new interest to the industry. Combining medical technology with human touch, the healthcare industry diagnoses, treats, and administers care around the clock -- responding to the needs of millions of people. Pharmaceuticals should remain one of the widest-margin industries, with prospects enhanced by demographic growth in the elderly and new drugs stemming from discoveries in genomics and biotechnology. Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help limit expense. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas.

Equity Markets has reviewed Allos Therapeutics, Inc. as a biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics. The Company is focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN targets the inhibition of dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, thereby interfering with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis and triggering cancer cell death. The full research report on Allos Therapeutics, Inc. (NASDAQ: ALTH) is available here:

Equity Markets is covering Spectrum Pharmaceuticals, Inc. as a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company has a fully developed commercial infrastructure that markets and sells two drugs in the United States, Zevalin and Fusilev. The Company has several drug candidates in development, which include apaziquone (EOquin), which is being studied in two large Phase III clinical trials for non-muscle invasive bladder cancer (NMIBC). (NASDAQ: SPPI) is available here:

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information